Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jianhui Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8710-1722; OpenAlex author ID A5052012838. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 8

  1. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  2. GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence. Co-author DOI 10.1016/j.tranon.2026.103044↗
  3. Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing. Co-author DOI 10.1007/s12672-025-02293-w↗
  4. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. First author DOI 10.1038/s41419-025-08049-2↗
  5. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. First author DOI 10.1097/js9.0000000000002242↗
  6. Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. Co-author DOI 10.1186/s13046-025-03563-9↗
  7. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Co-author DOI 10.3390/ijms222010944↗
  8. Stress-induced phosphoprotein 1 promotes pancreatic cancer progression through activation of the FAK/AKT/MMP signaling axis. Co-author DOI 10.1016/j.prp.2019.152564↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 6 shared papers, 2021–2026 · strength 1.38
  2. Jin Xu · 4 shared papers, 2021–2026 · strength 0.88
  3. Qingcai Meng · 4 shared papers, 2021–2026 · strength 0.84
  4. Zhen Tan · 4 shared papers, 2021–2026 · strength 0.84
  5. Chen Liang · 4 shared papers, 2021–2026 · strength 0.84
  6. Zeyin Rong · 3 shared papers, 2025–2026 · strength 0.72
  7. Jie Hua · 3 shared papers, 2021–2026 · strength 0.62
  8. Wei Wang · 3 shared papers, 2021–2026 · strength 0.62
  9. Yangyi Li · 2 shared papers, 2025–2026 · strength 0.53
  10. Jin Xu · 1 shared paper, 2026 · strength 0.27
  11. Miaoyan Wei · 1 shared paper, 2026 · strength 0.27
  12. Chao-Yi Zhang · 1 shared paper, 2025 · strength 0.26
  13. Saimeng Shi · 1 shared paper, 2025 · strength 0.23
  14. Qinglin Fei · 1 shared paper, 2025 · strength 0.23
  15. Duancheng Guo · 1 shared paper, 2025 · strength 0.23
  16. Long‐Yun Ye · 1 shared paper, 2025 · strength 0.23
  17. Weiding Wu · 1 shared paper, 2025 · strength 0.23
  18. Kaizhou Jin · 1 shared paper, 2025 · strength 0.23
  19. Heng Zhu · 1 shared paper, 2025 · strength 0.22
  20. Rong Tang · 1 shared paper, 2025 · strength 0.22
  21. Xiaomeng Liu · 1 shared paper, 2025 · strength 0.22
  22. Xu He · 1 shared paper, 2025 · strength 0.22
  23. Mingming Xiao · 1 shared paper, 2025 · strength 0.22
  24. Qiong Du · 1 shared paper, 2025 · strength 0.22
  25. Jin Xu · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.